There is currently no standard treatment for patients with relapsed or refractory multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses promising agents for this patient population, including immunomodulatory agents, such as lenalidomide and pomalidomide; proteasome inhibitors, such as carfilzomib; and monoclonal antibodies, such as daratumumab and elotuzumab.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates